| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f38b248c0862a9fd61964e7f4e4c2276
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b774960516190273786c73adf2ab711 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-11001 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-11001 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
2020-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50b55035ffc8d5ab737d7a29de2e340f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_636940e32d0fbe0e7803923b11e75cec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65d617ade872b4797d7849511ed6b83d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cf05f1c78561275173c9f9f9496d5b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fb46edafb60123a1e941eec2747a675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fcf3ab150a0ac341467d85b227baac3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c743193a36c7628484ff2caca4cdb53d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_429f9d8e82894c4ba8f0a486a9a586cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adcd28866b2f708c9190735728ce142c |
| publicationDate |
2022-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022220480-A1 |
| titleOfInvention |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders |
| abstract |
The present invention relates to a PAK-1 and/or PAK-2 inhibitor for use in the treatment of NLRP3 inflammasome mediated IL-1beta dependent disorders in a subject in need thereof. Inventors invalidated PAK-1 and/or PAK-2 in BMDM by transfecting siRNA targeting either PAK-1 and/or PAK-2 (PAK-3 is predominantly expressed in the brain). After 72 hours of siRNA expression, cells were stimulated by LPS and the CNF1 toxin for 8 hours. They observed that cells invalidated for PAK-1 had a reduced Caspase-1 activation compared to the control cells or cells invalidated for PAK-2. Similar results were observed when the IL-1β maturation was monitored. Confirming this data, the use of PAK-1 inhibitors (IPA-3 and FRAX597) were sufficient to block the IL-1β maturation observed in macrophages treated with LPS and CNF1 as well as Caspase-1 activation measured using FAM-FLICA. |
| priorityDate |
2019-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |